Phase II trial of standard versus increased transfusion volume in Ugandan children with acute severe anemia.
BMC Med
; 12: 67, 2014 Apr 25.
Article
em En
| MEDLINE
| ID: mdl-24767094
ABSTRACT
BACKGROUND:
Severe anemia (SA, hemoglobin <6 g/dl) is a leading cause of pediatric hospital admission in Africa, with significant in-hospital mortality. The underlying etiology is often infectious, but specific pathogens are rarely identified. Guidelines developed to encourage rational blood use recommend a standard volume of whole blood (20 ml/kg) for transfusion, but this is commonly associated with a frequent need for repeat transfusion and poor outcome. Evidence is lacking on what hemoglobin threshold criteria for intervention and volume are associated with the optimal survival outcomes.METHODS:
We evaluated the safety and efficacy of a higher volume of whole blood (30 ml/kg; Tx30 n = 78) against the standard volume (20 ml/kg; Tx20 n = 82) in Ugandan children (median age 36 months (interquartile range (IQR) 13 to 53)) for 24-hour anemia correction (hemoglobin >6 g/dl primary outcome) and 28-day survival.RESULTS:
Median admission hemoglobin was 4.2 g/dl (IQR 3.1 to 4.9). Initial volume received followed the randomization strategy in 155 (97%) patients. By 24-hours, 70 (90%) children in the Tx30 arm had corrected SA compared to 61 (74%) in the Tx20 arm; cause-specific hazard ratio = 1.54 (95% confidence interval 1.09 to 2.18, P = 0.01). From admission to day 28 there was a greater hemoglobin increase from enrollment in Tx30 (global P <0.0001). Serious adverse events included one non-fatal allergic reaction and one death in the Tx30 arm. There were six deaths in the Tx20 arm (P = 0.12); three deaths were adjudicated as possibly related to transfusion, but none secondary to volume overload.CONCLUSION:
A higher initial transfusion volume prescribed at hospital admission was safe and resulted in an accelerated hematological recovery in Ugandan children with SA. Future testing in a large, pragmatic clinical trial to establish the effect on short and longer-term survival is warranted. TRIAL REGISTRATION ClinicalTrials.Gov identifier NCT01461590 registered 26 October 2011.
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Transfusão de Sangue
/
Hemoglobina A
/
Anemia
Tipo de estudo:
Clinical_trials
/
Guideline
/
Prognostic_studies
Limite:
Child, preschool
/
Female
/
Humans
/
Infant
/
Male
País como assunto:
Africa
Idioma:
En
Ano de publicação:
2014
Tipo de documento:
Article